Oncolytic HSV1716 attenuates tumor-killing activity of infected primary NK cells
Oncolytic herpes simplex virus type-1 (HSV1)–based therapies engage innate immune responses, including natural killer (NK) cells, which are regarded as antiviral effector cells that eliminate virus-infected tumor targets. In this study, we examined int…